Viktige studier og Cochrane Reviews

Viktige Symbicort®-studier som viser:

• Effektiv reduksjon av risiko for eksaserbasjoner ^1,2
• Forlenget tid til første eksaserbsjon med 158 dager (vs placebo)¹
• Forbedret lungefunksjon; FEV1 og morgen PEF ^1,2
• Forbedret livskvalitet ^1,2
• Redusert symptomscore ^1,2
• Færre trengte medisinsk behandling ^1,2

1. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22:s912-919 2. Szafranski W et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur Respir J 2003; 21:74-81

 Cochrane Database of Systematic Reviews., 2005.
 - Noen av de viktigste reviews vedrørende KOLS

Nannini, L; Cates, CJ; Lasserson, TJ; Pool, P; Cochrane Airways Group Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstuctive pulmonary disease.
Monninkhof, EM; van der Valk, PDLPM; van der Palen, J; van Herwaarden, CLA; Partidge, MR; Walters, EH; Zielhuis, GA Cochrane Airways Group
Self-management education for chronic obstructive pulmonary disease.
van der Meer, RM; Wagena, EJ; Ostelo, RWJG; Jacobs, JE; van Schayck, CP Cochrane Airways Group
Smoking cessation for chronic obstructive pulmonary disease.

Lacasse, Y; Brosseau, L; Milne, S; Martin, S; Wong, E; Guyatt, GH; Goldstein, RS; White, J Cochrane Airways Group
Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Wood-Baker, RR; Gibson, PG; Hannay, M; Walters, EH; Walters, JAE Cochrane Airways Group
Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Ta kontakt med Medisinsk informasjonstjeneste hos AstraZeneca AS dersom du ønsker papirkopi av disse eller andre studier.

Utarbeidet av AstraZeneca AS ved Cand. Scient. Anne Hilde Røsvik Oppdatert 08.09.2005